Search Clinical Trials in the European Union

1-2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
181-200 of 653 trials

Basal Cell Carcinomas: Patidegib Gel 2%

We are studying a new gel for adults with Gorlin syndrome to see if it helps prevent basal cell carcinomas on the face. The trial will also check how safe and tolerable the gel is for patients.

Gorlin Syndrome1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyHematology

Advanced Breast and Gastric Cancers: Disitamab Vedotin with Tucatinib

We are studying a new combination of disitamab vedotin and tucatinib for patients with advanced breast and gastric cancers. The goal is to find the best dose and evaluate its safety and effectiveness.

HER2 Positive Breast CancerOesophageal AdenocarcinomaGastric Cancer1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Thyroid Eye Disease: VRDN-001 Treatment Study

We are testing the safety and tolerability of a new monoclonal antibody, VRDN-001, in people with thyroid eye disease. This study involves receiving intravenous infusions to see how well the treatment is tolerated.

Thyroid Eye Disease1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesEndocrinologyOphthalmology

Membranous Nephropathy: Dapagliflozin Treatment Study

We are investigating how dapagliflozin affects immune activity and kidney function in patients with Membranous Nephropathy. This study may help us understand its potential benefits for managing this condition.

Membranous Nephropathy1-2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineNephrology

Nasal Treatment: HY-133 Bacteriophage Endolysin

We are testing a new nasal treatment to see if it is safe and effective for patients. This study also explores how it affects the nasal microbiome.

Nasal Colonization with MSSA1-2 yearsSafety phase (I)Infectious DiseasesOtolaryngology

Lung Cancer: IPH5201 and Durvalumab Treatment Study

We are studying a combination of two treatments before and after surgery for patients with early-stage non-small cell lung cancer. The goal is to see if this approach improves tumor response and safety compared to standard treatments.

Non-Small Cell Lung Cancer (NSCLC) Stage II and III1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Cirrhosis and Ascites: Fecal Microbiota Transfer Capsules

We are testing the safety of FMT capsules for patients with cirrhosis and ascites to see if they may help reduce immune activation. This study will also look for signs of effectiveness compared to a placebo.

Cirrhosis of the Liver1-2 yearsEfficacy phase (II)Standard MedicinesCost ReimbursementGastroenterologyHepatology

Cardiac Anesthesia: Eleveld Model for Propofol and Remifentanil

We are studying how well a new model predicts drug levels of propofol and remifentanil in patients undergoing heart surgery. This research may help improve anesthesia safety and effectiveness during cardiac procedures.

Heart Disorders1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal MedicineOtolaryngology

Pancreatic Exocrine Insufficiency: Creon® Therapy Study

We are exploring how Creon® may help improve nutrition and quality of life for patients with pancreatic exocrine insufficiency after total gastrectomy. The study also looks at weight changes and gastrointestinal symptoms.

Pancreatic Exocrine Insufficiency1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Cannabidiol for Refractory Childhood Epilepsy

We are studying whether adding CBD can help children with hard-to-treat epilepsy manage their seizures better. The trial also looks at how this treatment affects the quality of life for patients and their families.

Refractory Epilepsy1-2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Ulcerative Colitis: Eltrekibart Treatment Study

We are studying whether eltrekibart can help adults with moderately to severely active ulcerative colitis achieve remission. This trial compares the effects of eltrekibart to a placebo.

Ulcerative Colitis1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Advanced Triple-Negative Breast Cancer: TONIC-3 Trial

We are studying new immunotherapy strategies for patients with advanced triple-negative breast cancer. The goal is to see if these treatments are safe and effective, and to learn more about how tumors respond to them.

Metastatic Triple Negative Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Self-Administration of Elranatamab for Multiple Myeloma

We are exploring whether patients with multiple myeloma can safely administer Elranatamab at home. The study will assess the feasibility, safety, and impact on quality of life for both patients and their caregivers.

Multiple Myeloma1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHematologyOncology

Breast Cancer Treatment for Women 70+: Radiation vs. Hormone Therapy

We are comparing radiation therapy and hormone therapy for older women with early-stage luminal A-like breast cancer. The goal is to see which treatment better controls cancer and improves quality of life.

Breast Cancer1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Atopic Dermatitis: Amlitelimab Treatment Study

We are studying two dosing schedules of amlitelimab for people aged 12 and older with moderate-to-severe atopic dermatitis. The goal is to see if it helps maintain treatment response compared to stopping treatment.

Atopic Dermatitis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

ROS1-Positive Lung Cancer: REPotrectinib Study

We are testing a new treatment for patients with ROS1-positive non-small cell lung cancer and active brain metastasis. The study aims to see how well it works in shrinking brain tumors and to assess its safety.

ROS1-positive Non-Small Cell Lung Cancer with Brain Metastasis1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNeurologyOncology

INBRX-109 for Advanced Solid Tumors, Including Sarcomas

We are studying a new treatment, INBRX-109, in combination with chemotherapy for adults and adolescents with advanced solid tumors like Ewing sarcoma and colorectal cancer. The goal is to assess its safety and how well it works compared to current treatments.

Advanced or Metastatic Solid Tumors1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncology

Crohn’s Disease: MORF-057 Treatment Study

We are testing a new medication, MORF-057, for adults with moderately to severely active Crohn’s disease. The study aims to see if it improves symptoms and endoscopic results compared to a placebo.

Crohn's Disease1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesGastroenterologyInternal Medicine

Heart Failure: Balcinrenone/Dapagliflozin Study

We are evaluating a new treatment combining balcinrenone and dapagliflozin for patients with heart failure and kidney problems. The study aims to see if this combination reduces heart-related events and improves health compared to standard treatment.

Chronic Heart Failure1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCardiologyNephrology

Kidney Transplant Rejection: Efgartigimod PH20 SC

We are studying a new treatment for kidney transplant recipients facing antibody-mediated rejection. The trial aims to evaluate the safety and how well this medication works compared to a placebo.

Antibody-Mediated Rejection1-2 yearsEfficacy phase (II)16-20 visitsStandard MedicinesCost ReimbursementInternal MedicineNephrology